On this page
Zynlonta
loncastuximab tesirine-lpyl
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Zynlonta
Proper name
loncastuximab tesirine-lpyl
Licence type
351(a)
BLA number
761196
Applicant
ADC Therapeutics SA
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 10MG | For Injection | Intravenous | Single-Dose Vial | Rx | April 23, 2021 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | April 23, 2028 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |